Mark Vaeck has more than 30 years of experience in the biotech and pharma industry.
As a serial entrepreneur he raised more than €100 million in equity financing for the biotech companies he helped creating. In 2008, he co-founded Complix and was appointed CEO in May 2010.
Prior to this, in 2006, Mark co-founded ActoGeniX (Belgium) and served as its CEO until 2010. He was also the founding CEO of Ablynx (Belgium) from 2001 until 2006. Before joining Ablynx, Mark was COO of Ceres Inc. (US), a NASDAQ listed company developing innovative technologies for biofuel production. From 1987 to 1998, he held several business development and general management positions in the biotech and pharma industry, including at UCB, Chiron, Keygene and PGS. Mark holds a PhD in Immunology from the Free University of Brussels